Nisa Investment Advisors LLC Increases Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN)

Nisa Investment Advisors LLC boosted its stake in Myriad Genetics, Inc. (NASDAQ:MYGN) by 182.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,417 shares of the company’s stock after acquiring an additional 7,381 shares during the period. Nisa Investment Advisors LLC’s holdings in Myriad Genetics were worth $313,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Allspring Global Investments Holdings LLC grew its position in shares of Myriad Genetics by 90.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 8,805 shares of the company’s stock valued at $188,000 after purchasing an additional 4,193 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Myriad Genetics by 80.5% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 334,717 shares of the company’s stock worth $7,620,000 after purchasing an additional 149,234 shares in the last quarter. Nordea Investment Management AB lifted its position in Myriad Genetics by 5.6% during the 1st quarter. Nordea Investment Management AB now owns 128,903 shares of the company’s stock worth $2,769,000 after acquiring an additional 6,807 shares in the last quarter. Texas Permanent School Fund Corp boosted its stake in shares of Myriad Genetics by 1.2% in the first quarter. Texas Permanent School Fund Corp now owns 77,485 shares of the company’s stock valued at $1,652,000 after purchasing an additional 889 shares during the period. Finally, AMH Equity Ltd acquired a new stake in shares of Myriad Genetics during the first quarter valued at about $2,345,000. Hedge funds and other institutional investors own 99.02% of the company’s stock.

Myriad Genetics Trading Down 0.2 %

Shares of Myriad Genetics stock opened at $17.57 on Thursday. Myriad Genetics, Inc. has a 12 month low of $15.99 and a 12 month high of $29.30. The company has a quick ratio of 1.78, a current ratio of 1.96 and a debt-to-equity ratio of 0.05. The business has a fifty day simple moving average of $25.18 and a 200-day simple moving average of $24.80.

Myriad Genetics (NASDAQ:MYGN) last issued its earnings results on Tuesday, August 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.06. Myriad Genetics had a negative net margin of 19.35% and a negative return on equity of 5.64%. The company had revenue of $211.50 million during the quarter, compared to analyst estimates of $206.44 million. During the same quarter last year, the business posted ($0.21) EPS. The company’s revenue for the quarter was up 15.3% on a year-over-year basis. Equities analysts predict that Myriad Genetics, Inc. will post -0.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on MYGN shares. JPMorgan Chase & Co. raised their price target on shares of Myriad Genetics from $17.00 to $20.00 and gave the stock an “underweight” rating in a research report on Wednesday, August 7th. Morgan Stanley initiated coverage on Myriad Genetics in a research note on Thursday, September 19th. They issued an “equal weight” rating and a $32.00 target price on the stock. Scotiabank boosted their price objective on Myriad Genetics from $29.00 to $34.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, August 13th. Wells Fargo & Company initiated coverage on shares of Myriad Genetics in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $35.00 target price for the company. Finally, TD Cowen boosted their price objective on Myriad Genetics from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Wednesday, August 7th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $28.91.

Insider Activity at Myriad Genetics

In other Myriad Genetics news, CEO Paul J. Diaz sold 15,000 shares of the stock in a transaction on Friday, October 11th. The shares were sold at an average price of $22.93, for a total transaction of $343,950.00. Following the transaction, the chief executive officer now directly owns 962,378 shares of the company’s stock, valued at $22,067,327.54. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Myriad Genetics news, Director Heinrich Dreismann sold 10,000 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $27.05, for a total value of $270,500.00. Following the sale, the director now directly owns 121,648 shares in the company, valued at $3,290,578.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Paul J. Diaz sold 15,000 shares of Myriad Genetics stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $22.93, for a total value of $343,950.00. Following the sale, the chief executive officer now directly owns 962,378 shares in the company, valued at approximately $22,067,327.54. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,012 shares of company stock valued at $1,900,485. 2.10% of the stock is currently owned by corporate insiders.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.